Jeroen Noordink
About Jeroen Noordink
Jeroen Noordink is the Senior Director of Business Insights & Analytics for the EU Cluster at Bristol Myers Squibb in Utrecht, Netherlands. He has over 20 years of experience in finance and business planning roles, having previously worked at Celgene, Noordinc., Novartis, Stg. Wijkwelzijn Zuidwijken, and Ernst & Young Accountants.
Company
Jeroen Noordink is currently serving as the Senior Director of Business Insights & Analytics for the European Cluster at Bristol Myers Squibb. He joined the organization in July 2020 and is based in Utrecht, Netherlands. His role primarily involves overseeing business insights and analytics to support strategic decision-making across the European Cluster.
Title
Jeroen Noordink holds the title of Senior Director, Business Insights & Analytics EU-Cluster at Bristol Myers Squibb. In this position, he is responsible for leading business analytics initiatives and providing actionable insights to drive business performance in the European region.
Education and Expertise
Jeroen Noordink studied at Nyenrode Business University, where he completed his MSc in Accountancy from 2001 to 2008. He also attended Het Assink - Atheneum from 1992 to 1999. With over 20 years of experience in the fields of finance and business planning, Noordink has developed substantial expertise in accountancy and business process control.
Professional Background
Over the course of his career, Jeroen Noordink has worked in various capacities across multiple organizations. His previous roles include Director of Finance & Business Planning for Central Northern Europe at Celgene, Owner at Noordinc., Business Process Controller at Novartis, and Head of Financial Administration at Stg. Wijkwelzijn Zuidwijken. He began his career as an Assistant Accountant at Ernst & Young Accountants.
Career at Celgene
From 2014 to 2020, Jeroen Noordink served as the Director of Finance & Business Planning for Central Northern Europe at Celgene. During his six-year tenure, he played a key role in financial planning and business strategy, gaining extensive experience in the pharmaceutical sector before transitioning to his current role at Bristol Myers Squibb.